Ticagrelor Patent Expiration
Ticagrelor is used for reducing the rate of cardiovascular events, including myocardial infarction and stroke, in patients with coronary artery disease or who had acute coronary syndrome. It was first introduced by Astrazeneca Pharmaceuticals Lp
Ticagrelor Patents
Given below is the list of patents protecting Ticagrelor, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Brilinta | US10300065 | Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction | Jan 27, 2036 | Astrazeneca |
| Brilinta |
US10300065 (Pediatric) | Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction | Jul 27, 2036 | Astrazeneca |
| Brilinta | US6251910 | 1,2,3-triazolo[4,5-d]pyrimidines as P2T receptor antagonists |
Jul 15, 2018
(Expired) | Astrazeneca |
| Brilinta | US6251910 | 1,2,3-triazolo[4,5-d]pyrimidines as P2T receptor antagonists |
Jul 15, 2018
(Expired) | Astrazeneca |
| Brilinta | US6525060 | Triazolo(4,5-d)pyrimidine compounds |
Dec 02, 2019
(Expired) | Astrazeneca |
| Brilinta | US6525060 | Triazolo(4,5-d)pyrimidine compounds |
Dec 02, 2019
(Expired) | Astrazeneca |
| Brilinta | US7250419 | Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition |
Dec 02, 2019
(Expired) | Astrazeneca |
| Brilinta | US7250419 | Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition |
Dec 02, 2019
(Expired) | Astrazeneca |
| Brilinta | US7265124 | Cristalline and amorphous form of a triazolo (4,5-D) pyridimine compound |
Jul 09, 2021
(Expired) | Astrazeneca |
| Brilinta | US7265124 | Cristalline and amorphous form of a triazolo (4,5-D) pyridimine compound |
Jul 09, 2021
(Expired) | Astrazeneca |
| Brilinta | US8425934 | Pharmaceutical compositions | Apr 17, 2030 | Astrazeneca |
| Brilinta |
US8425934 (Pediatric) | Pharmaceutical compositions | Oct 17, 2030 | Astrazeneca |
| Brilinta | USRE46276 | Triazolo(4,5-D)pyrimidine compounds | Oct 30, 2024 | Astrazeneca |
| Brilinta |
USRE46276 (Pediatric) | Triazolo(4,5-D)pyrimidine compounds | Apr 30, 2025 | Astrazeneca |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳
Ticagrelor Generics
Several generic applications have been filed for Ticagrelor. The first generic version for Ticagrelor was by Watson Laboratories Inc and was approved on Sep 4, 2018. And the latest generic version is by Alkem Laboratories Ltd and was approved on Apr 21, 2023.
Given below is the list of companies who have filed for Ticagrelor generic.
1. SIGMAPHARM LABS LLC
Sigmapharm Laboratories Llc has filed for 1 generic for Ticagrelor. Given below are the details of the strengths of this generic introduced by Sigmapharm Labs Llc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 90MG | tablet | Discontinued | ORAL | N/A | Apr 7, 2020 |
2. MYLAN
Mylan Pharmaceuticals Inc has filed for 2 different strengths of generic version for Ticagrelor. Given below are the details of the strengths of this generic introduced by Mylan.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 90MG | tablet | Discontinued | ORAL | N/A | Jul 9, 2021 |
| 60MG | tablet | Discontinued | ORAL | N/A | Jul 9, 2021 |
3. AMNEAL
Amneal Eu Ltd has filed for 1 generic for Ticagrelor. Given below are the details of the strengths of this generic introduced by Amneal.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 90MG | tablet | Discontinued | ORAL | N/A | Jan 23, 2019 |
4. SUNSHINE
Sunshine Lake Pharma Co Ltd has filed for 1 generic for Ticagrelor. Given below are the details of the strengths of this generic introduced by Sunshine.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 90MG | tablet | Discontinued | ORAL | N/A | Apr 6, 2020 |
5. ALKEM LABS LTD
Alkem Laboratories Ltd has filed for 1 generic for Ticagrelor. Given below are the details of the strengths of this generic introduced by Alkem Labs Ltd.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 90MG | tablet | Prescription | ORAL | AB | Apr 21, 2023 |
6. HISUN PHARM HANGZHOU
Hisun Pharmaceutical Hangzhou Co Ltd has filed for 1 generic for Ticagrelor. Given below are the details of the strengths of this generic introduced by Hisun Pharm Hangzhou.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 90MG | tablet | Prescription | ORAL | AB | Jan 23, 2019 |
7. WATSON LABS INC
Watson Laboratories Inc has filed for 2 different strengths of generic version for Ticagrelor. Given below are the details of the strengths of this generic introduced by Watson Labs Inc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 60MG | tablet | Discontinued | ORAL | N/A | Sep 4, 2018 |
| 90MG | tablet | Discontinued | ORAL | N/A | Sep 4, 2018 |